Ocugen Inc (NASDAQ:OCGN) has been one of the notable gainers in recent months owing to its deal to distribute Indian company Bharat Biotech’s COVID 19 vaccine Covaxin in the United States. Yesterday, the stock was in focus once again and jumped by as much as 14% in anticipation of the company’s submission of the emergency use authorization application for the vaccine.
The company stated yesterday that the emergency use authorization application is going to be filed with the United States Food and Drug Administration at some point next month.
The news of the imminent application is a major development considering the fact that Ocugen had spent several months in talks with the FDA regarding this matter. In this regard, it should be noted that the company also noted that the new guidance with respect to EUA by the FDA is going to help Covaxin in meeting all the necessary conditions for approval.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.